Author:
Okita K,Morales A M,Dean A C,Johnson M C,Lu V,Farahi J,Mandelkern M A,London E D
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Psychiatry and Mental health,Molecular Biology
Reference74 articles.
1. Substance Abuse and Mental Health Services Administration (SAMHSA). Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health 2015.
2. Chomchai C, Chomchai S . Global patterns of methamphetamine use. Curr Opin Psychiatry 2015; 28: 269–274.
3. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 2001; 158: 1206–1214.
4. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377–382.
5. Boileau I, Rusjan P, Houle S, Wilkins D, Tong J, Selby P et al. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker? J Neurosci 2008; 28: 9850–9856.